Abstract library

63 results for "Monti".
#2712 HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors (NET) and Hormone Receptor Positive Expression
Introduction: We have shown immunohistochemistry (IHC) expression of estrogen (ER) and progesterone receptors (PR) in 20.8% and 18.8% of 96 NET patients (pts). An old clinical trial (Mortel C, 1984) suggested antitumor effects of estrogen/progesterone-directed therapies in NET. Yet the effects of an antiestrogen agent in NET pts whose tumor express ER and/or PR are unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Prof Rachel Riechelmann
#2796 Avelumab for Advanced Merkel Cell Carcinoma in the Netherlands; A Nationwide Survey
Introduction: Merkel cell carcinoma (MCC) is a rare, tumor of the skin associated with high recurrence rates and poor survival. Clinical trials have shown activity of checkpoint inhibitors targeting programmed death-(ligand)-1 (PD-(L)1). Avelumab is the only PD-L1 inhibitor that has been approved in the Netherlands for advanced/metastatic MCC (mMCC).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Sonja Levy
#2837 Development and Initial Validation of a Brief Questionnaire to Assess Patient Satisfaction with Self-Injection of Lanreotide Autogel: Results During a Home Training Programme
Introduction: The long acting formulation of lanreotide autogel(LAN) can facilitate self-injection (SI) by patients or caregivers at home, avoiding visits to health centers. Training by nurses is required to ensure successful SI. Patient satisfaction(PS) is an important outcome of SI and home care programs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD PhD Jorge Hernando-Cubero
#2898 Novel Preclinical Models of Small Bowel Neuroendocrine Tumors for Drug Screening
Introduction: The incidence of neuroendocrine tumors (NETs) from the small bowel (SBNETs) has increased markedly over the past several decades. Many patients with these tumors present with metastatic disease, and research into new treatment options for these tumors have been hindered by the limited number of patient-derived SBNET cell lines and in vivo models available for drug testing.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Assistant Profes Po Hien Ear
Authors: Ear P H, Tran C, Li G, Kaemmer C, ...
#2914 Safety Profile and Adverse Events of Special Interest for Surufatinib in Chinese Patients with Advanced Extra-Pancreatic Neuroendocrine Tumors: Analysis of the Phase 3 SANET-ep Trial
Introduction: The previously reported SANET-ep trial (NCT02588170) demonstrated surufatinib significantly improves progression-free survival (PFS) in patients (pts) with advanced extrapancreatic neuroendocrine tumors (epNETs) compared to placebo; median PFS (9.2 vs. 3.8 months; HR = 0.334, 95% CI 0.223 to 0.499, p
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Jie Li
Authors: Li J, Xu J, Zhou Z, Bai C, ...
#3000 Patients with Somatostatin Receptor Type 2-Negative Neuroendocrine Tumors Have Sustained Inferior Survival Rates in a Propensity Score-Matched Analysis
Introduction: Sufficient expression of somatostatin receptor type 2 (SST2) in neuroendocrine tumors (NETs) is crucial for treatment with unlabelled somatostatin analogues (SSAs), or peptide receptor radionuclide therapy (PRRT) using radio-labelled SSAs. Impaired prognosis has been described for SST2-negative NET patients, however studies comparing matched SST2-positive and -negative subjects are missing.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Julie Refardt
#3029 Adrenocortical Carcinoma Metastasic in Adult on Complete Response with EDP-M and Local Therapy: A Single Case Report
Introduction: Adrenocortical carcinoma (ACC) in adults is a rare tumor (incidence 0.7-2/1000000/year). Median overall survival is 3-4 years and five-year survival is 0-28% in metastatic disease. The only curative therapy is complete surgical resection, plus adjuvant therapy depending on poor prognostic factors (ENSAT stage III, R1 resection or Ki67>10%). Both recurrent oligometastatic disease and patients who respond to systemic treatment (ST), a radical approach with surgery or local therapy (LT) may be treatment options.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Rocío Morales Herrero
#3065 Intensive Personalized Program for Daily Living with Neuroendocrine Neoplasms as a Chronic Disease: Preliminary Results
Introduction: Introduction: Neuroendocrine neoplasms (NENs) are increasingly viewed as chronic diseases as a result of more effective treatments and procedures. As with any life changing events, patient and family transition to a new “normal” requires attitudinal adjustments. The Intensive Personalized Program for Daily Living with Neuroendocrine Neoplasms is a pilot program transitioning patients and their primary familial carer to a new “normal”.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Mike Rosenberg
#42 Chemotherapy in the Treatment of Progressive, Undifferentiated Neuroendocrine Carcinomas: a Single-Center Experience.
Introduction: Treatment of poorly differentiated neuroendocrine tumors (NET) usually includes chemotherapeutic intervention. However, both the rarity and the heterogeneity of the disease have led to relatively few clinical trials. This study evaluated the outcome of two chemotherapy regimens in patients suffering from undifferentiated and histologically confirmed NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Timo Deutschbein